A Phase 1 Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq) in Patients With Advanced or Metastatic Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Uliledlimab (Primary)
Indications Cancer; Carcinoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors TRACON Pharmaceuticals

10 Sep 2024 According to an I-MAB Biopharma media release, a poster presentation of PK/PD modeling data for uliledlimab in 3 phase 3 studies at the International Association for the Study of Lung Disease (IASLD)'s 2024 World Conference on Lung Cancer (WCLC 2024) held September 7-10, 2024 in San Diego, CA.
08 Mar 2023 Status changed from active, no longer recruiting to completed, according to a TRACON Pharmaceuticals media release.
11 May 2022 According to a TRACON Pharmaceuticals media release, the company complete this trial permitting I-Mab the opportunity to terminate the license for $9M this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com